Advantages and Disadvantages of Topical Tofacitinib in Chronic Hand Eczema

Efficacy and safety of Topical Tofacitinib in hand eczema A quasi experimental single armed study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080312

Enrollment

Registered

2025-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L308- Other specified dermatitis

Interventions

Intervention1: Efficacy of Topical Tofacitinib in Chronic Hand eczema: Topical Tofacitinib will be given to all patient .Effectiveness and safety will be recorded based on Hand eczema severity score i

Eligibility

Inclusion criteria

Inclusion criteria: patients of hand eczema diagnosed clinically or histopathologically hand eczema lasting for more than or equal to 3 months or with two episodes per year age more than 18 years

Exclusion criteria

Exclusion criteria: preganancy and lactation very severe hand eczema( hand eczema severity index score more than 117) patient on concurrent systemic immunosuppressive or with in last 4 weeks patient on concurrent topical immunomodulators/immunosuppressants or within last 4 weeks

Design outcomes

Primary

Measure	Time frame
To find out the efficacy of topical tofacitinib in treatment of chronic hand eczemaTimepoint: Base line second week fourth week	—

Secondary

Measure	Time frame
To assess the safety of topical tofacitinib in treatment of chronic hand eczemaTimepoint: 1 month	—

Countries

India

Contacts

Public ContactDR TANISHA NAYAK

IMS & SUM HOSPITAL BHUBANESWAR

bikashkar@soa.ac.in09937428181

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026